This randomized study demonstrates significant improvements in cardiac function and mental health in AMI patients, highlighting the role of Shexiang Baoxin Pill and Baduanjin.
Background: To evaluate the efficacy and safety of the Shexiang Baoxin Pill (SBP) combined with Baduanjin exercise in the treatment of patients with acute myocardial infarction (AMI). Methods: A total of 150 AMI patients who underwent percutaneous coronary intervention (PCI) were randomly assigned to 3 groups: Group A received conventional therapy combined with SBP and Baduanjin, Group B received conventional therapy with Baduanjin, and Group C received only conventional therapy. The study was conducted over 6 months, with primary outcomes measured using left ventricular ejection fraction (LVEF) for cardiac function, Hamilton Anxiety Scale (HAMA) for anxiety, Hamilton Depression Rating Scale (HAMD) for depression, and Myocardial Infarction Dimensional Assessment Scale (MIDAS) for quality of life. Safety was assessed by monitoring the incidence of adverse events. Results: Cardiac function significantly improved in all groups, with the most pronounced improvement observed in Group A (LVEF increased from 50.09% to 56.10%, P < .001). Group A also showed significant reductions in anxiety and depression scores (HAMA: from 18.30 to 10.07; HAMD: from 20.98 to 11.53, P < .05) and a substantial enhancement in quality of life (MIDAS: from 85.86 to 51.52, P < .05). No severe adverse events were reported. Conclusion: The integrative approach of SBP and Baduanjin with conventional therapy significantly improved cardiac function, mental health, and quality of life in patients with AMI, offering a safe and effective adjunct to conventional care.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: